HIV-associated lipodystrophy: from fat injury to premature aging

Trends in Molecular Medicine

Volumn 16, Issue 5, 2010, Pages 218-229

  Caron Debarle, Martine ^a,b   Lagathu, Claire ^a,b   Boccara, Franck ^a,b,c   Vigouroux, Corinne ^a,b,c   Capeau, Jacqueline ^a,b,c  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PLUS FOSAMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; GLITAZONE DERIVATIVE; HYDROCORTISONE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADIPOSE TISSUE; BODY FAT; BROWN ADIPOSE TISSUE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG WITHDRAWAL; DYSLIPIDEMIA; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HIV ASSOCIATED LIPODYSTROPHY; HORMONE RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOATROPHY; LIPOHYPERTROPHY; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREMATURE AGING; REVIEW; SIDE EFFECT; CHEMICALLY INDUCED; DRUG EFFECTS; HIV INFECTIONS; LIPODYSTROPHY; PATHOLOGY;

ADIPOSE TISSUE; AGING, PREMATURE; ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; LIPODYSTROPHY;

EID: 77952420363     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.03.002     Document Type: Review

References (99)

1. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352 (2005) 48-62
2. Carr A., and Cooper D.A. Adverse effects of antiretroviral therapy. Lancet 356 (2000) 1423-1430
3. Hammond E., and Nolan D. Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy. Curr. Opin. HIV AIDS 2 (2007) 274-281
4. Caron M., et al. Adipocyte dysfunction in response to antiretroviral therapy: clinical, tissue and in-vitro studies. Curr. Opin. HIV AIDS 2 (2007) 268-273
5. Villarroya F., et al. Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim. Biophys. Acta 180 (2010) 392-399
6. Nguyen A., et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med. 9 (2008) 142-150
7. Arpadi S.M., et al. Longitudinal changes in regional fat content in HIV-infected children and adolescents. AIDS 23 (2009) 1501-1509
8. Guaraldi G., and Baraboutis I.G. Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities. J. Antimicrob. Chemother. 64 (2009) 437-440
9. Rosen E.D., and Spiegelman B.M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444 (2006) 847-853
10. Aron-Wisnewsky J., et al. Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J. Clin. Endocrinol. Metab. 94 (2009) 4619-4623
11. De Pauw A., et al. Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations. Am. J. Pathol. 175 (2009) 927-939
12. Koh E.H., et al. Essential role of mitochondrial function in adiponectin synthesis in adipocytes. Diabetes 56 (2007) 2973-2981
13. Sekiya M., et al. Oxidative stress induced lipid accumulation via SREBP1c activation in HepG2 cells. Biochem. Biophys. Res. Commun. 375 (2008) 602-607
14. Deveaud C., et al. Regional differences in oxidative capacity of rat white adipose tissue are linked to the mitochondrial content of mature adipocytes. Mol. Cell Biochem. 267 (2004) 157-166
15. Lihn A.S., et al. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am. J. Physiol. Endocrinol. Metab. 285 (2003) E1072-1080
16. Szendroedi J., and Roden M. Ectopic lipids and organ function. Curr. Opin. Lipidol. 20 (2009) 50-56
17. Suganami T., et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 84-91
18. Villarroya J., et al. Mitochondrial DNA: an up-and-coming actor in white adipose tissue pathophysiology. Obesity (Silver Spring) 17 (2009) 1814-1820
19. Furukawa S., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114 (2004) 1752-1761
20. Garg A., and Agarwal A.K. Lipodystrophies: disorders of adipose tissue biology. Biochim. Biophys. Acta 1791 (2009) 507-513
21. Capeau, J. et al. (2010) Human lipodystrophies: genetic and acquired diseases of adipose tissue. In Adipose Tissue Development: From Animal Models to Clinical Conditions. (Levy-Marchal, C., Pénicaud, L., eds), pp. 1-20, Endocr Dev. Basel, Karger
22. Boutet E., et al. Seipin deficiency alters fatty acid Delta9 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy. Biochimie. 91 (2009) 796-803
23. Worman H.J., et al. Laminopathies and the long strange trip from basic cell biology to therapy. J. Clin. Invest. 119 (2009) 1825-1836
24. Caron M., et al. Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence. Cell Death Differ. 14 (2007) 1759-1767
25. Béréziat V., et al. Remodeling of adipose tissue from lipodystrophic patients with LMNA mutations: presence of fibrosis and mitochondrial alterations but no inflammation. Diabetologia 251 (2009) S254-S255
26. Morton N.M. Obesity and corticosteroids: 11beta-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol. Cell Endocrinol. 316 (2009) 154-164
27. Miller J., et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 4 (2003) 293-301
28. Nolan D., et al. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir. Ther. 8 (2003) 617-626
29. van Vonderen M.G., et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One 4 (2009) e5647
30. Pinti M., et al. Anti-HIV drugs and the mitochondria. Biochim. Biophys. Acta 1757 (2006) 700-707
31. Cote H.C. Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction. Curr. Opin. HIV AIDS 2 (2007) 253-260
32. Boothby M., et al. Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir. Ther. 14 (2009) 1089-1100
33. Dube M.P., et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 19 (2005) 1807-1818
34. Shlay J.C., et al. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. J. Acquir. Immune Defic. Syndr. 48 (2008) 53-62
35. Mallon P.W. Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies. Curr. Opin. HIV AIDS 2 (2007) 282-292
36. Galli M., et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch. Intern. Med. 162 (2002) 2621-2628
37. Flint O.P., et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol. Pathol. 37 (2009) 65-77
38. Haubrich R.H., et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23 (2009) 1109-1118
39. Galli M., et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J. Acquir. Immune. Defic. Syndr. 34 (2003) 58-61
40. Jacobson D.L., et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin. Infect. Dis. 40 (2005) 1837-1845
41. McComsey G., et al. Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study. Clin. Infect. Dis. 48 (2009) 1323-1326
42. Wells J.C. Sexual dimorphism of body composition. Best Pract. Res. Clin. Endocrinol. Metab. 21 (2007) 415-430
43. Stankov M.V., et al. Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 54 (2010) 280-287
44. Caron M., et al. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir. Ther. 13 (2008) 27-38
45. Walker U.A., et al. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir. Ther. 11 (2006) 25-34
46. Lagathu C., et al. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir. Ther. 12 (2007) 489-500
47. El Hadri K., et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J. Biol. Chem. 279 (2004) 15130-15141
48. Djedaini M., et al. Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem. Biophys. Res. Commun. 386 (2009) 96-100
49. Kovsan J., et al. Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes--relevance for partial lipodystrophy. Am. J. Physiol. Endocrinol. Metab. 296 (2009) E315-322
50. Vatier C., et al. HIV protease inhibitors differently affect human subcutaneous and visceral fat: they induce IL-6 production and alter lipid storage capacity in subcutaneous but nos visceral adipose tissue explants. Antiviral Therapy 13 Suppl. 4 (2008) A15-A16
51. Crowe S.M., et al. The macrophage: the intersection between HIV infection and atherosclerosis. J. Leukoc. Biol. 87 (2010) 589-598
52. Giralt M., et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir. Ther. 11 (2006) 729-740
53. Bastard J.P., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine. Netw. 17 (2006) 4-12
54. Otake K., et al. HIV-1 Nef protein in the nucleus influences adipogenesis as well as viral transcription through the peroxisome proliferator-activated receptors. AIDS 18 (2004) 189-198
55. Shrivastav S., et al. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol. Endocrinol. 22 (2008) 234-247
56. McComsey G.A., et al. Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir. Ther. 13 (2008) 715-722
57. Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top. HIV Med. 15 (2007) 114-117
58. Mallon P.W., et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J. Infect. Dis. 191 (2005) 1686-1696
59. Kratz M., et al. Reduced adipogenic gene expression in thigh adipose tissue precedes human immunodeficiency virus-associated lipoatrophy. J. Clin. Endocrinol. Metab. 93 (2008) 959-966
60. Calmy A., et al. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy. HIV Med. 9 (2008) 101-110
61. Sievers M., et al. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy. J. Infect. Dis. 200 (2009) 252-262
62. Kim M.J., et al. Mitochondrial DNA content, an inaccurate biomarker of mitochondrial alteration in human immunodeficiency virus-related lipodystrophy. Antimicrob. Agents Chemother. 52 (2008) 1670-1676
63. Gerschenson M., et al. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J. Antimicrob. Chemother. 63 (2009) 1244-1250
64. Negredo E., et al. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin. Infect. Dis. 49 (2009) 892-900
65. Sevastianova K., et al. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am. J. Physiol. Endocrinol. Metab. 295 (2008) E85-91
66. Kim M.J., et al. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Antivir. Ther. 12 (2007) 1273-1283
67. Sutinen J., et al. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 47 (2004) 1668-1671
68. Deveaud C., et al. Site specific alterations of adipose tissue mitochondria in 3′-azido-3′-deoxythymidine (AZT)-treated rats: an early stage in lipodystrophy?. Biochem. Pharmacol. 70 (2005) 90-101
69. Nisoli E., et al. Multiple symmetric lipomatosis may be the consequence of defective noradrenergic modulation of proliferation and differentiation of brown fat cells. J. Pathol. 198 (2002) 378-387
70. Franceschi C., et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev. 128 (2007) 92-105
71. Wu D., et al. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J. Immunol. 179 (2007) 4829-4839
72. Tarr P.E., et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J. Infect. Dis. 191 (2005) 1419-1426
73. Wangsomboonsiri W., et al. Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. Clin. Infect. Dis. 50 (2010) 597-604
74. Hendrickson S.L., et al. Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 51 (2009) 111-116
75. Zanone Poma B., et al. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 22 (2008) 1769-1778
76. Rodriguez-Novoa S., et al. Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J. 6 (2006) 234-245
77. Wohl D., et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J. Acquir. Immune Defic. Syndr. 48 (2008) 44-52
78. Samaras K., et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 30 (2007) 113-119
79. De Wit S., et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 31 (2008) 1224-1229
80. Vigouroux C., et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 17 (2003) 1503-1511
81. Crane H.M., et al. Lipoatrophy and lipohypertrophy are independently associated with hypertension. HIV Med. 10 (2009) 496-503
82. Boccara, F. et al. (2010) HIV protease inhibitors activate the adipocyte renin-angiotensin system. Antivir. Ther. 15(3): In press
83. Lemoine M., et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 20 (2006) 387-395
84. Ingiliz P., et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 49 (2009) 436-442
85. Snijder M.B., et al. Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: the Hoorn study. Diabetes Care 27 (2004) 372-377
86. Vasto S., et al. Inflammatory networks in ageing, age-related diseases and longevity. Mech. Ageing Dev. 128 (2007) 83-91
87. Florez H., and Troen B.R. Fat and inflammaging: a dual path to unfitness in elderly people?. J. Am. Geriatr. Soc. 56 (2008) 558-560
88. Guaraldi G., et al. Coronary aging in HIV-infected patients. Clin. Infect. Dis. 49 (2009) 1756-1762
89. Lo J., et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 24 (2010) 243-253
90. Effros R.B., et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin. Infect. Dis. 47 (2008) 542-553
91. Sutinen J. The effects of thiazolidinediones on metabolic complications and lipodystrophy in HIV-infected patients. PPAR Res. 2009 (2009) 373524
92. Slama L., et al. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir. Ther. 13 (2008) 67-76
93. McComsey, G. et al. (2010) A 48-week randomized study of uridine supplementation vs. switch to TDF on limb fat, mitochondrial function, inflammation and bone mineral density in HIV lipoatrophy. In 17th Conference on Retroviruses and Opportunistic Infections, 342
94. Sutinen J., et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir. Ther. 12 (2007) 97-105
95. Mallon P.W., et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study. AIDS 20 (2006) 1003-1010
96. Falutz J., et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 22 (2008) 1719-1728
97. van Leuven S.I., et al. Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!. Curr. Opin. HIV AIDS 2 (2007) 324-331
98. Saves M., et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin. Infect. Dis. 34 (2002) 1396-1405
99. Calmy A., et al. A new era of antiretroviral drug toxicity. Antivir. Ther. 14 (2009) 165-179